{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:05:24Z","timestamp":1789783524232,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.critrevonc.2008.07.013","type":"journal-article","created":{"date-parts":[[2008,8,31]],"date-time":"2008-08-31T05:38:31Z","timestamp":1220161111000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis"],"prefix":"10.1016","volume":"69","author":[{"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2008.07.013_bib1","first-page":"106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib2","series-title":"Breast cancer facts & figures 2005\u20132006","author":"American Cancer Society","year":"2005"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1200\/JCO.1995.13.5.1144","article-title":"Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up","volume":"13","author":"Quiet","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib4","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.1991.9.9.1650","article-title":"Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study","volume":"9","author":"Rosen","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.1989.7.9.1239","article-title":"Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years","volume":"7","author":"Rosen","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","article-title":"Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women","volume":"17","author":"Heshmati","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib9","doi-asserted-by":"crossref","unstructured":"Hadji P. Aromatase inhibitor-associated bone loss in breast cancer. Touch Brief: Eur Oncol Dis 2007:35\u20138. <http:\/\/www.touchbriefings.com\/pdf\/2789\/Hadji.pdf>.","DOI":"10.17925\/EOH.2007.0.1.18"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","article-title":"Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study","volume":"20","author":"Geisler","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib16","first-page":"2089","article-title":"In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients","volume":"4","author":"Geisler","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib19","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1054\/bjoc.2001.1729","article-title":"The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer","volume":"84","author":"Saarto","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors. Results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Int Med"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib23","first-page":"1511","article-title":"In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer","volume":"1","author":"Dowsett","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib24","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bjc.1996.531","article-title":"Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer","volume":"74","author":"Geisler","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2008.07.013_bib26","first-page":"5s","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the \u2018Arimidex\u2019, Tamoxifen, Alone or in Combination (ATAC) trial","volume":"24","author":"Coleman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib29","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer","volume":"23","author":"Lonning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s001980200001","article-title":"Changes in bone mineral density with age in men and women: a longitudinal study","volume":"13","author":"Warming","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623453","article-title":"Consensus development statement: who are candidates for prevention and treatment for osteoporosis?","volume":"7","author":"Lindsey","year":"1997","journal-title":"Osteoporos Int"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF01623429","article-title":"Peak bone mass","volume":"4","author":"Bonjour","year":"1994","journal-title":"Osteoporos Int"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01623436","article-title":"Postmenopausal bone loss and the risk of osteoporosis","volume":"4","author":"Christiansen","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib35","series-title":"Prevention and management of osteoporosis (WHO Technical Report Series 921)","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0039-128X(02)00046-6","article-title":"Regulation of estrogen synthesis in postmenopausal women","volume":"67","author":"Purohit","year":"2002","journal-title":"Steroids"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00198-003-1408-1","article-title":"Early menopause: increased fracture risk at older age","volume":"14","author":"van Der Voort","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib43","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib44","unstructured":"National Osteoporosis Foundation. NOF physician's guide: pharmacologic options. <www.nof.org\/physguide\/phamacologic.htm> [accessed 03.08.2007]."},{"key":"10.1016\/j.critrevonc.2008.07.013_bib45","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Int Med"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib46","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib47","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2008.07.013_bib48","first-page":"19s","article-title":"Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study","volume":"26","author":"Lester","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib49","unstructured":"Van Poznak C, Hannon R.A, Clack G. et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. In: Presented at the San Antonio Breast Cancer symposium. December 13\u201315 2007, San Antonio, Texas [abstract 502]."},{"key":"10.1016\/j.critrevonc.2008.07.013_bib50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib51","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.breast.2006.01.005","article-title":"Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program","volume":"15","author":"Aapro","year":"2006","journal-title":"Breast"},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2008.07.013_bib52","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","article-title":"Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update","volume":"33","author":"Brufsky","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib53","doi-asserted-by":"crossref","unstructured":"Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). In: Presented at the 5th European breast cancer conference. 21-25 March 2006. Nice, France [abstract 12].","DOI":"10.1016\/S1359-6349(06)80035-2"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib54","unstructured":"Schenk N, Lombart A, Frassoladti A, et al. The E-ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvantletrozole. In: Presented at the 14th European cancer conference (ECCO); 23-27 September 2007. Barcelona, Spain, [abstract 2008]."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib55","first-page":"S233","article-title":"Twenty-four month follow-up of zoledronic acid (ZA) on aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib57","first-page":"S8","volume":"106","author":"Gnant","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib58","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2008.07.013_bib59","first-page":"1006s","article-title":"Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12","volume":"26","author":"Gnant","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib60","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ncpendmet0121","article-title":"Drug insight: bisphosphonates for postmenopausal osteoporosis","volume":"2","author":"Chapurlat","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib62","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/JBMR.040508","article-title":"Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50\u201364 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA)","volume":"19","author":"Siris","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib63","first-page":"S25","article-title":"An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib64","unstructured":"Llombart A. Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (E-ZO-FAST trial). In: Presented at the 14th European cancer conference (ECCO). 23\u201327 September 2007, Barcelona, Spain [abstract 2044]."},{"key":"10.1016\/j.critrevonc.2008.07.013_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2474-3-11","article-title":"The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women","volume":"3","author":"Adachi","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.315.7102.221","article-title":"Bone density and risk of hip fracture in men and women: cross sectional analysis","volume":"315","author":"De Laet","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib67","doi-asserted-by":"crossref","unstructured":"Logman F, Heeg B., Botteman M., Marfatia A.A., van Hout B.A. Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: application to the United Kingdom. Presented at the 14th European cancer conference (ECCO). 23\u201327 September 2007, Barcelona, Spain [abstract 1146].","DOI":"10.1016\/S1359-6349(07)70665-1"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.07.013_bib68","first-page":"S187","article-title":"The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor","volume":"100","author":"Whannel","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2008.07.013_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","author":"Hadji","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842808001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842808001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:26:48Z","timestamp":1760902008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842808001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1040842808001546"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2008.07.013","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2008.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}